サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1728281

プロゲステロン市場- 世界の産業規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競合別セグメント、2020-2030年

Progesterone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

プロゲステロン市場- 世界の産業規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競合別セグメント、2020-2030年
出版日: 2025年05月16日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

プロゲステロンの世界市場は、2024年に2億392万米ドルと評価され、2030年には2億4,258万米ドルに達し、予測期間中にCAGR 1.89％で成長すると予測されています。

プロゲステロンは、ホルモン補充療法（HRT）、避妊薬、不妊治療、獣医学的用途に広く使用されている重要なホルモンです。排卵を調整し、妊娠を維持する上で重要な役割を果たすことから、ヒトと動物の両方の健康分野で不可欠なものとなっています。不妊率の増加や体外受精などの生殖補助医療（ART）へのアクセスの拡大が、プロゲステロンに基づく製剤の需要を促進しています。また、生殖や更年期の健康に対する世界の意識の高まりも、特に新興国において市場の成長を後押ししています。しかし、規制の複雑さ、長期的なホルモン療法による潜在的な副作用、原料供給や製造コストの変動といった課題に市場は引き続き直面しています。

市場概要
予測期間 2026-2030
市場規模：2024年 2億392万米ドル
市場規模：2030年 2億4,258万米ドル
CAGR：2025年～2030年 1.89%
急成長セグメント ダイレクト
最大市場 アジア太平洋

市場促進要因

製薬業界の成長

主な市場課題

安全性への懸念と副作用

主要市場動向

更年期障害に対する意識の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のプロゲステロン市場に与える影響

第5章 世界のプロゲステロン市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 販売チャネル別（直接、間接）
    • 用途別（ホルモン補充療法、不妊治療、月経障害、月経前症候群（PMS）、その他）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米のプロゲステロン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州のプロゲステロン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域のプロゲステロン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米のプロゲステロン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのプロゲステロン市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 世界のプロゲステロン市場：SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • NAARI PHARMA Pvt. Ltd
  • La Chandra Pharmalab
  • BGP Laboratories Private Limited
  • V M Lifescience
  • Mankind Pharma Ltd
  • Bhugan Lifescience Pvt Ltd
  • Abcures Biosciences LLP
  • Symbiotec Pharmalab
  • Granth Pharma Pvt Ltd
  • Emote Lifesciences LLP

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 29045

The Global Progesterone Market was valued at USD 203.92 million in 2024 and is projected to reach USD 242.58 million by 2030, growing at a CAGR of 1.89% during the forecast period. Progesterone is a vital hormone widely used across hormone replacement therapies (HRT), contraceptives, fertility treatments, and veterinary applications. Its critical role in regulating ovulation and sustaining pregnancy makes it essential in both human and animal health sectors. Increasing infertility rates and expanding access to assisted reproductive technologies (ART), such as IVF, are fueling demand for progesterone-based formulations. Rising global awareness of reproductive and menopausal health is also driving market growth, particularly in emerging economies. However, the market continues to face challenges from regulatory complexities, potential adverse effects of long-term hormone therapy, and fluctuations in raw material supply and production costs.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 203.92 Million
Market Size 2030USD 242.58 Million
CAGR 2025-20301.89%
Fastest Growing SegmentDirect
Largest MarketAsia Pacific

Key Market Drivers

Growth in Pharmaceutical Industry

The expanding focus on women's health, particularly related to menopause, fertility, and hormonal disorders, is a major factor driving demand for progesterone. As more women seek treatment for conditions like perimenopause, endometriosis, and PCOS, progesterone is increasingly used in HRT and therapeutic solutions. Rising age-related hormonal concerns in developed markets with greater healthcare access further support this trend.

In addition, the global burden of infertility is intensifying demand for ART procedures, in which progesterone is commonly administered to support embryo implantation and early pregnancy. With approximately 1 in 6 adults experiencing infertility globally, the need for effective, affordable, and accessible fertility care has grown. Progesterone's integral role in IVF and similar procedures is contributing to its rising use in fertility medications across both developed and developing markets, where awareness and accessibility of such treatments continue to expand.

Key Market Challenges

Safety Concerns and Side Effects

One of the major challenges in the progesterone market is the range of safety concerns and adverse effects associated with its long-term or high-dosage use, especially in HRT and fertility therapies. Common side effects include fatigue, bloating, mood changes, and headaches, while more severe risks such as thromboembolic events, cardiovascular complications, and increased cancer risk-particularly when used alongside estrogen-have raised caution.

In ART procedures, progesterone is essential for luteal phase support, but hormone supplementation may result in conditions like ovarian hyperstimulation syndrome (OHSS) and weight gain, which could deter treatment adherence. These health concerns affect prescription rates and patient trust, posing limitations to widespread adoption despite progesterone's clinical importance in reproductive care.

Key Market Trends

Rise in Menopause Awareness

Growing global awareness about menopause and related hormonal imbalances is shaping demand for effective hormone replacement therapies that include progesterone. With rising life expectancy and an expanding population of women aged 50 and above, the need for symptom management and quality-of-life improvements is increasing. Progesterone, when used with estrogen in HRT, mitigates risks such as endometrial cancer, making it a critical component of balanced therapy.

The trend toward bioidentical hormones, which closely replicate the body's natural hormone structure, is gaining traction. Bioidentical progesterone is increasingly preferred over synthetic alternatives due to its perceived safety and better compatibility with the body, making it a popular choice among women seeking natural options for menopause symptom management. This shift is fueling innovation and driving growth in the global progesterone market.

Key Market Players

  • NAARI PHARMA Pvt. Ltd
  • La Chandra Pharmalab
  • BGP Laboratories Private Limited
  • V M Lifescience
  • Mankind Pharma Ltd
  • Bhugan Lifescience Pvt Ltd
  • Abcures Biosciences LLP
  • Symbiotec Pharmalab
  • Granth Pharma Pvt Ltd
  • Emote Lifesciences LLP

Report Scope

In this report, the Global Progesterone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Progesterone Market, By Sales Channel:

  • Direct
  • Indirect

Progesterone Market, By End Use:

  • Hormone Replacement Therapy
  • Infertility Treatment
  • Menstrual Disorders
  • Premenstrual Syndrome (PMS)
  • Others

Progesterone Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Progesterone Market.

Available Customizations

Global Progesterone Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Progesterone Market

5. Global Progesterone Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Hormone Replacement Therapy, Infertility Treatment, Menstrual Disorders, Premenstrual Syndrome (PMS), Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Progesterone Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Progesterone Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Progesterone Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Progesterone Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Progesterone Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Progesterone Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Progesterone Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Progesterone Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Progesterone Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Progesterone Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Progesterone Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Progesterone Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Progesterone Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Progesterone Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Progesterone Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Progesterone Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. South America Progesterone Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Progesterone Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Progesterone Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Progesterone Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Progesterone Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Progesterone Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Progesterone Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Progesterone Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Progesterone Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. NAARI PHARMA Pvt. Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. La Chandra Pharmalab
  • 15.3. BGP Laboratories Private Limited
  • 15.4. V M Lifescience
  • 15.5. Mankind Pharma Ltd
  • 15.6. Bhugan Lifescience Pvt Ltd
  • 15.7. Abcures Biosciences LLP
  • 15.8. Symbiotec Pharmalab
  • 15.9. Granth Pharma Pvt Ltd
  • 15.10. Emote Lifesciences LLP

16. Strategic Recommendations

17. About Us & Disclaimer